Edition:
United Kingdom

People: Prothena Corporation PLC (PRTA.OQ)

PRTA.OQ on NASDAQ Stock Exchange Global Select Market

10.00USD
19 Jun 2019
Change (% chg)

$-0.01 (-0.10%)
Prev Close
$10.01
Open
$10.03
Day's High
$10.22
Day's Low
$9.88
Volume
71,176
Avg. Vol
110,381
52-wk High
$15.91
52-wk Low
$8.66

Karp, Carol 

Ms. Carol D. Karp is Chief Regulatory Officer of the Company, since 2016. Prior to joining Prothena, she was an independent regulatory consultant to biotechnology and pharmaceutical companies. From 2013 to 2014, Ms. Karp was Senior Vice President, Regulatory Affairs and Compliance at Esperion Therapeutics, Inc. (a biotechnology company), and from 2010 to 2013, she was Vice President, Head of Global Regulatory Affairs, Pharmacovigilance & Risk Management at Janssen Alzheimer Immunotherapy, a Johnson & Johnson Company (a biopharmaceutical company). Previously, Ms. Karp held senior regulatory positions at Janssen Alzheimer Immunotherapy, CV Therapeutics, Inc., PowderJect Technologies, VIVUS, Inc., Cygnus, Inc. and Janssen Pharmaceutica. She earned her BA in Biology from the University of Rochester, where she is a member of the Board of Trustees.

Basic Compensation

Total Annual Compensation, USD 19,743
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 3,861,100
Fiscal Year Total, USD 3,880,840

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Lars Ekman

526,938

Gene Kinney

5,148,240

Tran Nguyen

3,260,720

Karin Walker

--

Wagner Zago

--

Arthur Homan

2,479,620
As Of  31 Dec 2017